MDSCs engage several diverse strategies to suppress tumor growth by inhibiting tumor cell cytotoxicity mediated by NK cells and by blocking the activation of tumor-reactive CD4+ and CD8+ T cells (62, 63). This evidence concerns the gene CD8A and neoplasm.